Subtype
Human Papillomavirus-Related Cervical Squamous Cell Carcinoma
CI-CAN-00005538Explore in graph →
2 active trials
- NCIt
- C27676
Loading cancer entity…
Subtype
CI-CAN-00005538Explore in graph →
Clinical trials
3 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (0)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06505551 | Phase 1/2 Study of Autologous SCG142 TCR T Cells in Patients With HPV16/52-positive Carcinoma | not yet recruiting | Phase 1 / Phase 2 | 66 | SCG Cell Therapy Pte. Ltd.INDUSTRY | 0 | Jul 17, 2024 | clinicaltrials |
| NCT03452332 |
| Stereotactic Body Radiation Therapy, Tremelimumab and Durvalumab in Treating Participants With Recurrent or Metastatic Cervical, Vaginal, or Vulvar Cancers |
| completed |
| Phase 1 |
| 20 |
| M.D. Anderson Cancer CenterOTHER |
| 1 |
| Sep 13, 2023 |
| clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials